Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes

Metabolism: Clinical and Experimental

Volumn 52, Issue 6, 2003, Pages 753-759

  Boden, Guenther ^a,b   Cheung, Peter ^a,b   Mozzoli, Maria ^a,b   Fried, Susan K ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE; ADIPONECTIN; CARBOHYDRATE; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; LEPTIN; LIPID; METFORMIN; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE; ANTIDIABETIC AGENT; PROTEIN; SIGNAL PEPTIDE; THIAZOLE DERIVATIVE;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; ARTICLE; CALORIMETRY; CELL SIZE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; ESTERIFICATION; FATTY ACID METABOLISM; FEMALE; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; GLYCOLYSIS; HUMAN; HYPERINSULINEMIA; LIPOLYSIS; MALE; METABOLIC PARAMETERS; MUSCLE BIOPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUBCUTANEOUS TISSUE; THIGH; BLOOD; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PATHOLOGY;

ADIPOCYTES; ADIPONECTIN; BLOOD GLUCOSE; CELL SIZE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; ESTERIFICATION; FATTY ACIDS; FEMALE; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; LIPOLYSIS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PROTEINS; THIAZOLES;

EID: 0038142248     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(03)00055-6     Document Type: Article

References (52)

1. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
2. Lehmann JM, Moor LB, Smith-Oliver TA, et al: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953-12956, 1995
3. Wilson TM, Cobb JE, Cowan DJ, et al: The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668, 1996
4. Tontonoz P, Hu E, Graves RA, et al: mPPAR gamma 2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224-1234, 1994
5. Kruszynska YT, Murkheryee R, Low L, et al: Skeletal muscle peroxisome proliferator-activated receptor-gamma expression in obesity and non-insulin dependent diabetes mellitus. J Clin Invest 101: 543-548, 1998
6. Tonotonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79:1147-1156, 1994
7. Ghazzi MN, Perez JE, Antonucci TK, et al: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 46:433-439, 1997
8. Chaput E, Saladin R, Silvestre M, et al: Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun 271:445-450, 2002
9. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10, 1997
10. Kemnitz JW, Elson DF, Roechner EB, et al: Pioglitazone increases sensitivity, reduces blood glucose, insulin and lipid levels, and lowers blood pressure in obese insulin resistant rhesus monkeys. Diabetes 43:204-211, 1994
11. Kelley DE, Goodpaster B, Wing RR, et al: Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 277:E1130-E1141, 1999
12. Shimoyama R, Ray TK, Savage CR Jr, et al: In vivo and in vitro effects of antiinsulin receptor antibodies. J Clin Endocrinol Metab 59:916-923, 1984
13. Molina JM, Baron AD, Edelman SV, et al: Use of variable tracer infusion method to determine glucose turnover in humans. Am J Physiol 258:E16-E23, 1990
14. Steele R, Wall JS, DeBodo RC, et al: Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187;15-24, 1956
15. Rossetti L, Lee YT, Ruiz J, et al: Quantitation of glycolysis and skeletal muscle glycogen synthesis in humans. Am J Physiol 265:E761-E769, 1993
16. Owen OE, Trapp VE, Reichard GA Jr, et al: Effects of therapy on the nature and quantity of fuels oxidized during diabetic ketoacidosis. Diabetes 29:365-372, 1980
17. Tappy L, Owen OE, Boden G: Effect of hyperinsulinemia on urea pool size and substrate oxidation rates. Diabetes 37:1212-1216, 1988
18. Boden G, Chen X, DeSantis RA, et al: Effects of insulin on fatty acid re-esterification in healthy subjects. Diabetes 42:1588-1593, 1993
19. Rosenblatt JI, Wolfe RR: Calculation of substrate flux using stable isotopes. Am J Physiol 254:E526-E531, 1988
20. Hirsch J, Gallian E: Methods for the determination of adipose cell size in man and animals. J Lipid Res 9:110-119, 1968
21. Lavau M, Susini C, Knittle J, et al: A reliable photomicrographic method for determining fat cell size. Proc Soc Exp Biol Med 156:251-256, 1975
22. Maggs DG, Buchanan TA, Burant CF, et al: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. Ann Intern Med 128:176-185, 1998
23. Ren JM, Marshall BA, Gulve EA, et al: Evidence from transgenic mice that glucose transport is rate-limiting for glycogen deposition and glycolysis in skeletal muscle. J Biol Chem 268:16113-16115, 1993
24. Cline GW, Petersen KF, Krssak M: Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341:240-246, 1999
25. Peraldi P, Zu M, Spiegelman BM: Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling. J Clin Invest 100:1863-1869, 1997
26. Saltiel AR, Kahn CR: Insulin signaling and the regulation of glucose and lipid metabolism. Nature 13:799-806, 2000
27. DeFronzo RA, Jacot E, Jequier E, et al: The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30:1000-1007, 1981
28. Sreenan S, Keck S, Fuller T, et al: Effects of troglitazone on substrate storage and utilization in insulin-resistant rats. Am J Physiol 39:E1119-E1129, 1999
29. Racette SB, Davis AO, McGill JB, et al: Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus. Metabolism 51:169-174, 2002
30. Mayerson AB, Hundal RS, Dufour S: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802, 2002
31. Miyazaki Y, Glass L, Triplitt C: Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210-2219, 2001
32. Santomauro ATMG, Boden G, Silva M, et al: Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48:1836-1841, 1999
33. Itani SI, Ruderman NB, Schmieder F, et al: Lipid induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C and IκB-α. Diabetes 51:2005-2011, 2002
34. Griffin ME, Marcucci M, Cline GW, et al: Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48:1270-1274, 1999
35. Scherer PE, Williams S, Fogliano M, et al: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:2746-2749, 1995
36. Maeda N, Takahashi M, Funahashi T, et al: PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001
37. Yang WS, Jeng CY, Wu TJ, et al: Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376-380, 2002
38. Hotta K, Funahashi T, Arita Y, et al: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Aterioscler Thromb Vasc Biol 20:1595-1599, 2002
39. 1H NMR spectroscopy study. Diabetologia 42:113-116, 1999
40. Comb TP, Berg AH, Obici S, et al: Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108:1875-1881, 2001
41. Yamauchi T, Kamon J, Waki H, et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
42. Zhang B, Graziano MP, Doebber TW, et al: Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 271:9455-9459, 1996
43. 12,14 prostaglandin J2A putative endogenous promoter of adipogenesis suppresses the ob gene. Metabolism 48:786-791, 1999
44. Cohen B, Novick D, Rubinstein M: Modulation of insulin activities by leptin. Science 274:1185-1188, 1996
45. Muller G, Ertl J, Gerl M et al: Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem 272:10585-10593, 1997
46. Wang Y, Kuropatwinski KK, White DW, et al: Leptin receptor action in hepatic cells. J Biol Chem 272:16216-16223, 1997
47. Oral EA, Simha V, Ruiz E, et al: Leptin-replacement therapy in lipodystrophy. N Engl J Med 346:570-578, 2002
48. Okuno A, Tamemoto H, Tobe K, et al: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998
49. DeSouza CJ, Eckhardt M, Gagen K, et al: Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50:1863-1871, 2001
50. Hevener AL, Reichart D, Janez A, et al: Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male Wistar rats. Diabetes 50:2316-2322, 2001
51. El-Kebbi IM, Roser S, Pollet RJ: Regulation of glucose transport by pioglitazone in culture muscle cells. Metabolism 43:953-958, 1994
52. Burant CF, Sreenan S, Hirango K, et al: Troglitazone action is independent of adipose tissue. J Clin Invest 100:2900-2908, 1997